Phase Ib Study of Drozitumab Combined with First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer

被引：33
|
作者：
Lima, Caio M. Rocha [1 ,2 ]
Bayraktar, Soley [1 ,2 ]
Flores, Aurea M. [1 ,2 ]
MacIntyre, Jessica [1 ,2 ]
Montero, Alberto [1 ,2 ]
Baranda, Joaquina C. [3 ]
Wallmark, John [4 ]
Portera, Chia [5 ]
Raja, Rajiv [5 ]
Stern, Howard [5 ]
Royer-Joo, Stephanie [5 ]
Amler, Lukas C. [5 ]
机构：
[1] Univ Miami, Div Hematol Oncol, Miami, FL 33136 USA
[2] Univ Miami Hosp & Clin, Sylvester Comprehens Canc Ctr, Miami, FL USA
[3] Univ Kansas, Med Ctr, Dept Med Oncol, Kansas City, KS 66103 USA
[4] Associates Oncol Hematol PC, Rockville, MD USA
[5] Genentech Inc, San Francisco, CA 94080 USA
来源：
CANCER INVESTIGATION | 2012年 / 30卷 / 10期
关键词：
Drozitumab; Metastatic colorectal cancer; Apo2; ligand; Apoptosis; Toxicity; Efficacy; CLINICAL-TRIALS; CHEMOTHERAPY;
D O I：
10.3109/07357907.2012.732163
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In this multicenter phase Ib study, drozitumab was given in combination with the mFOLFOX6 regimen and bevacizumab in patients with previously untreated, locally advanced recurrent or metastatic colorectal cancer on day 1 of every 14-day cycle. Nine patients were treated at 2 different cohort dose levels of drozitumab. No dose-limiting toxicities occurred at either dose level and the maximum tolerated dose was not reached. Two patients had a partial response of 4.93 and 4.96 months duration. Cohort 2 dose level is the recommended starting dose level for future trials.
引用
收藏
页码：727 / 731
页数：5
相关论文
共 50 条
  • [21] Cediranib With mFOLFOX6 Versus Bevacizumab With mFOLFOX6 As First-Line Treatment for Patients With Advanced Colorectal Cancer: A Double-Blind, Randomized Phase III Study (HORIZON III)
    Schmoll, Hans-Joachim
    Cunningham, David
    Sobrero, Alberto
    Karapetis, Christos S.
    Rougier, Philippe
    Koski, Sheryl L.
    Kocakova, Ilona
    Bondarenko, Igor
    Bodoky, Gyoergy
    Mainwaring, Paul
    Salazar, Ramon
    Barker, Peter
    Mookerjee, Bijoyesh
    Robertson, Jane
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (29) : 3588 - 3595
  • [22] First-line durvalumab plus monalizumab, mFOLFOX6, and bevacizumab or cetuximab for metastatic microsatellite-stable colorectal cancer (MSS-CRC)
    Wainberg, Zev A.
    Diamond, Jennifer Robinson
    Curigliano, Giuseppe
    Deva, Sanjeev
    Bendell, Johanna C.
    Han, Sae-Won
    Kalyan, Aparna
    Naidoo, Jarushka
    Kim, Richard D.
    Patel, Sandip Pravin
    Kourtesis, Panagiotis
    Li, Xia
    Ascierto, Maria
    Song, Xuyang
    Das, Mayukh
    Segal, Neil Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [23] Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer
    Bekaii-Saab, Tanios S.
    Balser, Sigrid
    Lohmann, Ragna
    Daoud, Hasan
    Liedert, Bernd
    Schliephake, Dorothee
    COLORECTAL CANCER, 2022, 11 (01)
  • [24] Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Rivera, Fernando
    Valladares, Manuel
    Gea, Salvador
    Lopez-Martinez, Noemi
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (06) : 574 - 584
  • [25] Phase I study of first-line sunitinib (SU) plus modified FOLFOX6 (mFOLFOX6) in Japanese patients (pts) with metastatic colorectal cancer (mCRC)
    Hamaguchi, T.
    Yoshino, T.
    Ohtsu, A.
    Yamazaki, K.
    Shimada, Y.
    Kato, K.
    Yasui, H.
    Boku, N.
    EJC SUPPLEMENTS, 2009, 7 (02): : 340 - 340
  • [26] Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
    Yoshino, Takayuki
    Watanabe, Jun
    Shitara, Kohei
    Yasui, Hirofumi
    Ohori, Hisatsugu
    Shiozawa, Manabu
    Yamazaki, Kentaro
    Oki, Eiji
    Sato, Takeo
    Naitoh, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Hihara, Masamitsu
    Soeda, Junpei
    Yamamoto, Kouji
    Akagi, Kiwamu
    Ochiai, Atsushi
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
  • [27] Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
    D Cunningham
    R P W Wong
    G D'Haens
    J-Y Douillard
    J Robertson
    A M Stone
    E Van Cutsem
    British Journal of Cancer, 2013, 108 : 493 - 502
  • [28] Cediranib with mFOLFOX6 vs bevacizumab with mFOLFOX6 in previously treated metastatic colorectal cancer
    Cunningham, D.
    Wong, R. P. W.
    D'Haens, G.
    Douillard, J-Y
    Robertson, J.
    Stone, A. M.
    Van Cutsem, E.
    BRITISH JOURNAL OF CANCER, 2013, 108 (03) : 493 - 502
  • [29] PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer
    Yoshino, Takayuki
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Shitara, Kohei
    Yamazaki, Kentaro
    Watanabe, Jun
    Oki, Eiji
    Sato, Takeo
    Naitoh, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Mori, Ikuo
    Yamanaka, Kazunori
    Hihara, Masamitsu
    Soeda, Junpei
    Yamanaka, Takeharu
    Akagi, Kiwamu
    Ochiai, Atsushi
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [30] PARADIGM study: A multicenter, randomized, phase III study of mFOLFOX6 plus panitumumab or bevacizumab as first-line treatment in patients with RAS (KRAS/NRAS) wild-type metastatic colorectal cancer
    Muro, Kei
    Uetake, Hiroyuki
    Tsuchihara, Katsuya
    Shitara, Kohei
    Yamazaki, Kentaro
    Oki, Eiji
    Sato, Takeo
    Naitoh, Takeshi
    Komatsu, Yoshito
    Kato, Takeshi
    Iwasaki, Kouji
    Soeda, Junpei
    Hihara, Masamitsu
    Yamanaka, Takeharu
    Ochiai, Atsushi
    Yoshino, Takayuki
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345